Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation

Conditions

Kidney; Complications, Allograft

What is the purpose of this trial?

This study is designed to assess the effectiveness of eculizumab in recipients of kidney transplantation with donor-specific antibodies (DSA) and worsening kidney function and to assess if eculizumab improves endothelial cell injury in the kidney.

The investigators hypothesize that complement inhibition with eculizumab will reduce allograft injury, resulting from less complement-mediated injury of endothelial cells and less endothelial cell activation.



Participation Guidelines

Age:
18 Years - 65 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Alexion Pharmaceuticals
Sanjay Kulkarni
Dates:
March 2011
Last Updated:
March 27, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01327573